Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance: Resistance to Targeted Anti-Cancer Therapeutics, cartea 1
Editat de Benjamin Bonavidaen Limba Engleză Paperback – 19 mai 2015
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1071.20 lei 6-8 săpt. | |
Springer – 19 mai 2015 | 1071.20 lei 6-8 săpt. | |
Hardback (1) | 1074.40 lei 6-8 săpt. | |
Springer – 27 apr 2013 | 1074.40 lei 6-8 săpt. |
Din seria Resistance to Targeted Anti-Cancer Therapeutics
- 5% Preț: 703.57 lei
- 5% Preț: 1084.79 lei
- 5% Preț: 1073.88 lei
- 5% Preț: 1077.99 lei
- 5% Preț: 1080.88 lei
- 5% Preț: 1071.71 lei
- 5% Preț: 1077.08 lei
- 5% Preț: 1073.88 lei
- 5% Preț: 824.00 lei
- 5% Preț: 701.44 lei
- 5% Preț: 700.37 lei
- 5% Preț: 1071.71 lei
- 5% Preț: 697.85 lei
- 5% Preț: 1003.82 lei
- 5% Preț: 708.94 lei
- 5% Preț: 706.62 lei
- 5% Preț: 706.62 lei
- 5% Preț: 711.98 lei
- 5% Preț: 708.59 lei
- 5% Preț: 703.22 lei
Preț: 1071.20 lei
Preț vechi: 1127.57 lei
-5% Nou
Puncte Express: 1607
Preț estimativ în valută:
205.01€ • 212.95$ • 170.29£
205.01€ • 212.95$ • 170.29£
Carte tipărită la comandă
Livrare economică 03-17 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781489988416
ISBN-10: 1489988416
Pagini: 280
Ilustrații: XIII, 260 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.4 kg
Ediția:2013
Editura: Springer
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics
Locul publicării:New York, NY, United States
ISBN-10: 1489988416
Pagini: 280
Ilustrații: XIII, 260 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.4 kg
Ediția:2013
Editura: Springer
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics
Locul publicării:New York, NY, United States
Cuprins
Preface.- Multidrug resistance in cancer: a tale of ABC drug transporters.- Multidrug resistance: a role for membrane physics, pH and drug transporters.- Mechanisms and potential therapies for acquired resistance to inhibitors targeting the Raf or MEK kinases in cancer.- Mechanisms of resistance to targeted B-Raf therapies.- Role of β1integrins in the complication and drug resistance against lung cancer: targeting β1integrins to eradicate lung cancer.- Aldo-keto reductases as new therapeutic targets for colon cancer chemoresistance.- Overcoming drug resistance through elevation of ROS in cancer.- Cancer stem cells in resistance to cytotoxic drugs: implications in chemotherapy.- Two birds with a stone: molecular cancer therapy targeting signal transduction and DNA repair pathways.- Collateral sensitivity in drug-resistant tumor cells.- Human cancer resistance to trail-apoptotic pathway-targeted therapies.- The dark side of apoptosis.- Index.
Notă biografică
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
Textul de pe ultima copertă
Patients with various cancers are treated with conventional chemotherapeutic drugs and the majority responds well to such therapies. However, there is a subset of patients who does not respond initially and another subset who no longer responds to further treatments. Clearly, in those two subsets of patients, the cancer cells exhibit mechanisms of resistance. One of the main challenges facing us to date is to develop new therapies to treat patients with the resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance. Such mechanisms have revealed gene products that directly regulate resistance and are targets for therapy. Of interest, several FDA-approved drugs were able to overcome drug resistance and have been successfully used clinically. They have been used as monotherapy or synergized with other therapies for the treatment of resistant tumors.
This volume constitutes a total of twelve selective reviews by pioneer scientists in the field of cancer drug resistance. Specific mechanisms in drug resistance are reviewed and novel approaches are being proposed for therapeutic interventions. This volume is of general interest to scientists, clinicians, health care providers, and students.
This volume constitutes a total of twelve selective reviews by pioneer scientists in the field of cancer drug resistance. Specific mechanisms in drug resistance are reviewed and novel approaches are being proposed for therapeutic interventions. This volume is of general interest to scientists, clinicians, health care providers, and students.
Caracteristici
Describes the main mechanisms that govern tumor cell resistance to apoptotic stimuli Demonstrates the identification of existing agents or the development of new agents that can serve as sensitizing agents with other cytotoxics Features the latest research on the results of combining targeted sensitizing agents and conventional cytotoxic therapies